Long-term treatment with azacitidine for a higher risk myelodysplastic syndrome

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous group of malignant diseases, diverse in terms of clinical course, response to treatment, and cytogenetic and molecular. In the present paper, we reported a case of MDS-RCMD (classified according to WHO 2008); risk intermediate-2, in an 72-years old male patient who was treated 44 cycles azacytidine. After two cycles of AZA, has become independent of blood transfusions, and after six cycles haematological complete response was observed.